Explore our blog
Faster Prior Authorization Won't Solve Access for Rare and Specialty Therapies
Authors: Julia Wermerskirchen, PharmD & Sydney (Sheffield) Murner, MS
Capitalizing on Recovery: Building an IR Program for Biotech’s New Market Reality
Hannah Deresiewicz | EVP, Managing Director, IREC